GHRP-2 (pralmorelin) is a synthetic growth-hormone-releasing hexapeptide studied as a ghrelin-receptor agonist; this guide compiles reported examples for educational use only, not medical advice.
Standard Access: This compound's three paid filesAll-Access Lifetime: all 55 guides + every printableEducational content only
GHRP-2 Guide: Available Now
Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.
GHRP-2 at a glance
What it is
Synthetic hexapeptide amide D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2, INN pralmorelin (PubChem CID 6918245; C45H55N9O6; 818.0 g/mol; CAS 158861-67-7); growth hormone secretagogue and ghrelin-receptor (GHS-R1a) agonist
Researched for
Growth hormone release. Its established human use is diagnostic: the GHRP-2 stimulation test for growth hormone deficiency, used in Japan. No treatment indication was ever approved
Plasma half-life
Measured in the one published human study: elimination half-life 0.55 ± 0.14 h, about 33 minutes (ten children, intravenous); GH peaked at 0.42 ± 0.16 h
Regulatory status
No US drug label; FDA places injectable and nasal GHRP-2 in Category 2 (significant safety risks) of the 503B outsourcing list and GHRP-2 in Category 3 of the 503A pharmacy list; prohibited by WADA at all times (S2.2.4)
Educational reference. This page does not publish dose ranges or reconstitution arithmetic.
What it is / mechanism
GHRP-2, also known as pralmorelin, is a synthetic hexapeptide that mimics the endogenous hormone ghrelin. It binds to and activates the growth hormone secretagogue receptor (GHS-R1a), primarily in the pituitary and hypothalamus. Receptor activation signals through the Gq/11-phospholipase-C-IP3-calcium pathway, promoting the pulsatile release of endogenous growth hormone from pituitary somatotrophs. Unlike GHRH analogs, which act on a separate receptor, GHRP-2 works through the ghrelin pathway, so the two classes are reported to act synergistically when combined. Because it stimulates the body's own GH pulses rather than supplying exogenous hormone, it is often described in research literature as preserving physiological feedback. Three identity details matter when checking any of this against a registry. GHRP-2 is an amide, D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2, and its second residue, 3-(2-naphthyl)-D-alanine, is not one of the twenty amino acids the body uses to build proteins — the unnatural amino acid the FDA names in its safety assessment. The International Nonproprietary Name is pralmorelin, and its developer's code was KP-102. And in PubChem the name route and the CAS route agree: GHRP-2, pralmorelin and CAS 158861-67-7 all resolve to CID 6918245 (C45H55N9O6, 818.0 g/mol), while the dihydrochloride salt is a separate record, CID 9940988 (890.9 g/mol). That agreement is worth stating because its sibling does not share it: GHRP-6 sits under two PubChem records, and one of them lists “GHRP-2 Acetate” among its synonyms. The error runs one way only — GHRP-2’s own record names no GHRP-6. They are different molecules: GHRP-6 is His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, C46H56N12O6, 873.0 g/mol. A widely cited 1997 human study prints the GHRP-2 sequence with five residues, omitting the alanine; PubChem and the developer’s own pharmacology paper both give six. These are described mechanisms and registry facts, not statements of clinical benefit.
Researched effects
In research and clinical-diagnostic settings, GHRP-2 has been reported to produce sharp, dose-dependent increases in circulating growth hormone. The one human pharmacokinetic study timed that response: growth hormone peaked 0.42 ± 0.16 hours — about 25 minutes — after an intravenous dose in children, and fell with a half-life of 0.37 ± 0.15 hours (Pihoker et al., J Clin Endocrinol Metab 1998, PMID 9543135). The response is not specific to growth hormone: in healthy young adults GHRP-2 also raised prolactin, ACTH and cortisol (Arvat et al., Peptides 1997, PMID 9285939). Because it shares the ghrelin pathway, appetite stimulation is also commonly reported, though generally described as milder than with GHRP-6; that comparison is reported rather than measured side by side. Community reports discuss downstream interest in recovery, body composition, and sleep, but these are research findings and anecdotes, not guaranteed outcomes.
Evidence & regulatory status
Best-documented human use is diagnostic, not therapeutic. The GHRP-2 stimulation test is one of the tests recommended in Japan as an alternative to the insulin tolerance test for diagnosing adult growth hormone deficiency. In 71 adults aged 18–65 with pituitary tumours, each given all three tests before surgery (Kinoshita et al., Endocr J 2013;60(1):97-105, PMID 23079545), the median peak GH was 28.88 μg/L with GHRP-2, 9.38 with the insulin tolerance test and 4.43 with arginine; against the insulin tolerance test, GHRP-2 identified severe deficiency with 81.3% sensitivity and 94.5% specificity. Because the test also releases ACTH, a 2022 study of 36 patients recommends measuring ACTH during it to catch secondary adrenal insufficiency, which accompanied severe GH deficiency in 16 of 17 cases (Suzuki et al., J Endocr Soc 2022, PMID 35795807).
The treatment programme did not arrive. A 2004 drug profile (Drugs R D 2004;5(4):236-9, PMID 15230633) records the developer Kaken Pharmaceutical holding rights in Japan, a US and Canadian sublicence to Wyeth whose phase II programme in growth hormone deficiency “appears” to have been discontinued, a diagnostic application awaiting approval in Japan, and a phase II programme in short stature planned for launch in 2009. The diagnostic use is what reached the clinic, marketed in Japan as GHRP Kaken 100. No treatment indication has been approved anywhere.
Human pharmacokinetics rest on one small study. A PubMed search for GHRP-2 and pharmacokinetics returns 21 records; on reading them, one is a dedicated human pharmacokinetic study. Pihoker et al. (J Clin Endocrinol Metab 1998;83(4):1168-72, PMID 9543135) gave ten prepubertal children with short stature — nine boys and one girl, mean age 7.7 years — a single intravenous dose over one minute and sampled blood nine times over two hours. Disposition fitted a two-compartment model with an elimination half-life of 0.55 ± 0.14 hours, plasma clearance of 0.66 ± 0.32 L/h per kg and a volume of distribution of 0.32 ± 0.14 L/kg.
In rats the compound leaves mainly through bile. After an intravenous dose, plasma levels fell in two phases and 80% of the dose was recovered unchanged in bile within one hour (Nasu et al., Drug Metab Dispos 2005;33(10):1488-94, PMID 16033952). That is an animal finding, not a human measurement.
Regulatory, United States — two lists, two answers. FDA keeps separate lists for pharmacies compounding under section 503A and for outsourcing facilities under section 503B. On the 503B list (updated 21 March 2025) GHRP-2 is split by route: “for injectable and nasal routes of administration” it is in Category 2, bulk drug substances that raise significant safety risks; for every other route it is in Category 1, under evaluation. On the 503A list (updated 14 May 2026) GHRP-2 is in Category 3, nominated without adequate support. So the route this market uses is the one FDA placed in its safety-risk category.
The reason FDA gives is specific. Its safety-risk summary for GHRP-2 (entry dated 29 September 2023) states that injectable and nasal compounded GHRP-2 may pose a risk of immunogenicity because of the potential for aggregation and peptide-related impurities; that the unnatural amino acid adds to the complexity of characterising the peptide; and that FDA is aware of reports of serious adverse events in patients who received GHRP-2, including an increased insulin requirement to maintain blood glucose, deaths of critically ill study subjects, infection and pancreatitis — “though causality has not been established”.
Regulatory, sport: the World Anti-Doping Agency prohibits GHRP-2 at all times, in and out of competition, under section S2.2.4 (growth hormone releasing factors), which names the GH-releasing peptides as a class.
No trial of GHRP-2 is listed on ClinicalTrials.gov, but that does not mean there was never a development programme — and this page previously said flatly that no registered trial exists; that statement is withdrawn, because it could not be verified. ClinicalTrials.gov returns 0 studies with GHRP-2 or pralmorelin as the intervention; the control search growth hormone secretagogue returned 257 in the same mode on 27 September 2026, so the query works. The compound nonetheless went through a sponsor's development: its human pharmacokinetic study is titled a phase I study (PMID 9543135, 1998), Wyeth ran a phase II programme under the code GPA-748 (PMID 15230633), and Japan approved pralmorelin hydrochloride as a new active ingredient on 22 October 2004, as a diagnostic reagent for endocrine function (KEGG DRUG D02040). Most of that work predates routine public trial registration, and Japan's own registry could not be checked for this page, so whether any of those trials was registered is not established here. PubMed indexes 252 records mentioning GHRP-2.
No US drug label exists. An openFDA drug-label search for pralmorelin or GHRP-2 returns no matches; the same query for semaglutide returns 5, so the absence is real rather than a failed query.
Research-use: sold and handled as a research chemical only; not intended for human or veterinary therapeutic use, and not approved to treat, cure or prevent any condition.
Research timeline
Dated milestones taken from the primary records: the molecule's discovery, its first registered human study, the trials that shaped the evidence and the regulatory decisions. Each entry links to the record it comes from.
Cyril Bowers' group reports giving GHRP-2 to healthy younger and older men and women for 7-30 days, alone or with growth-hormone-releasing hormone, and finds that whether the growth-hormone response fades depends partly on how much and how often it is given. PMID 8887169
A Phase 1 study in ten children of short stature, the first pharmacokinetic study of GHRP-2 in children by its authors' account, measures a plasma elimination half-life of about 0.55 hours, roughly 33 minutes, after an intravenous injection. PMID 9543135
A drug-development profile records pralmorelin (GHRP-2, codes GPA 748 and KP-102) as a compound from the Polygen and Tulane University series led by Cyril Bowers, with its use as a diagnostic agent for growth hormone deficiency. PMID 15230633
In seven lean healthy men, GHRP-2 infused under the skin increased food intake at a buffet meal compared with saline, with every man eating more, mirroring the appetite effect of the hormone ghrelin. PMID 15699539
A Japanese validation study in 77 healthy people and 58 patients with growth hormone deficiency confirmed by the insulin tolerance test reports GHRP-2 as a simple, reproducible diagnostic test for adult growth hormone deficiency. PMID 17609397
FDA places GHRP-2 for injection and nasal use in Category 2 of its outsourcing-facility (503B) list, substances that raise significant safety risks, citing immunogenicity, an unnatural amino acid and reported serious adverse events, including deaths of critically ill study subjects, though causality was not established. FDA · compounding safety risks, Apr 22, 2026
Records checked Oct 4, 2026
Claims at a glance
The claims most often made about this compound, each with the strongest kind of evidence we found for it. The grade says what was studied, not whether the claim is true; the line beside it says what that study showed.
Builds muscle and burns fatNo study found. A PubMed search for GHRP-2 or pralmorelin with muscle, fat, strength or body-composition terms in humans returned 11 records; none measured those outcomes after GHRP-2. PubMed search, Oct 6, 2026
Increases appetiteHuman, randomised trial. In a randomised double-blind study of 19 lean and obese adults, buffet intake rose by about 10–34% against placebo, depending on the infusion level. PMID 16861611
Raises IGF-1Human, randomised trial. In a randomised five-day trial in 33 men with prolonged critical illness, IGF-1 returned to normal; in children treated for months, IGF-1 did not rise. PMID 12030918
Increases height in childrenHuman, non-randomised. In 15 short children given a nasal spray, growth speed rose over six months, with no control group and no significant change in IGF-1. PMID 9390009
Deepens sleepHuman, randomised trial. In seven healthy young men given GHRP-2 or saline in random order at night, slow-wave (deep) sleep did not increase. PMID 9612233
Raises growth hormone without affecting cortisol or prolactinHuman, non-randomised. In seven young volunteers tested head to head, GHRP-2 raised prolactin, ACTH and cortisol as much as hexarelin did; it is not selective for growth hormone. PMID 10195374
The reasoning behind each grade, study by study, is in this guide's Benefit & Outcome Review.
Grades checked Oct 6, 2026
A printable reference sheet with the compound's key facts, storage guidance and a vial record comes with All-Access Lifetime.
Half-life & pharmacokinetics
This page previously stated a plasma half-life of roughly 1-2 hours; that figure is withdrawn, because the published human measurement is shorter. In the one human pharmacokinetic study we could find (Pihoker et al., J Clin Endocrinol Metab 1998;83(4):1168-72, PMID 9543135), ten prepubertal children received a single intravenous dose over one minute and plasma GHRP-2 was measured by radioimmunoassay. Disposition fitted a two-compartment model and the elimination half-life was 0.55 ± 0.14 hours — about 33 minutes. Growth hormone itself peaked at 0.42 ± 0.16 hours, about 25 minutes, and was cleared with a half-life of 0.37 ± 0.15 hours. Four conditions travel with those numbers and are usually dropped: the subjects were children with short stature, not adults; the route was intravenous, not subcutaneous; there were ten of them, nine boys and one girl; and sampling stopped at two hours, so a slower phase after that could not have been seen. Treat 33 minutes as the best available human measurement rather than as a settled constant for adults or for injection under the skin.
Reported side effects & toxicology
Human safety data are limited, and GHRP-2 has no approved treatment use anywhere. The best-characterised effect beyond growth hormone is that it is not fully specific: in six healthy young adults, intravenous GHRP-2 also raised prolactin, ACTH and cortisol, with a prolactin effect smaller than that of TRH and an ACTH/cortisol effect similar to that of CRH (Arvat et al., Peptides 1997, PMID 9285939). That is why the Japanese diagnostic test is now recommended to measure ACTH as well (PMID 35795807). The species picture differs: in conscious rats the developer found ACTH and corticosterone release but no prolactin release (Doi et al., Arzneimittelforschung 2004, PMID 15646370). FDA’s safety-risk summary adds reports of serious adverse events in patients who received GHRP-2 — an increased insulin requirement to maintain blood glucose, deaths of critically ill study subjects, infection and pancreatitis — while stating that causality has not been established. Other commonly reported effects include increased appetite via the ghrelin pathway, transient water retention, tingling or head-rush sensations shortly after injection, and injection-site reactions. This is not a complete list and not medical advice.
Storage & handling
Lyophilized (powder): reported as stable refrigerated at 2-8 C, and for longer terms frozen; kept sealed and away from light.
Reconstituted (in bacteriostatic water): refrigerated at 2-8 C and typically reported as used within about 3-4 weeks; do not freeze the reconstituted solution.
References
Identity: PubChem CID 6918245 and CID 9940988. Pharmacokinetics: Pihoker et al., J Clin Endocrinol Metab 1998, PMID 9543135; Nasu et al., Drug Metab Dispos 2005, PMID 16033952. Endocrine specificity: Arvat et al., Peptides 1997, PMID 9285939; Doi et al., Arzneimittelforschung 2004, PMID 15646370. Diagnostic use: Kinoshita et al., Endocr J 2013, PMID 23079545; Suzuki et al., J Endocr Soc 2022, PMID 35795807. Development history: Drugs R D 2004, PMID 15230633; Japanese approval of 22 October 2004, KEGG DRUG D02040. Regulatory: FDA 503A and 503B bulk drug substance category lists and FDA's safety-risk summary for certain bulk drug substances; openFDA drug labels; ClinicalTrials.gov; WADA Prohibited List S2.2.4. Educational only, not medical advice.
Evidence File
The GHRP-2 Evidence File: 264 Papers, One Research Group on 38 of Its 59 Trials, and an Approval Nobody Mentions
GHRP-2 has a small, unusually concentrated literature: 264 PubMed records once every name is searched, 59 of them typed as clinical trials. Read the 59 and they sort cleanly. 31 are physiology experiments in healthy volunteers from one research group, which used GHRP-2 as a probe for how sex hormones, age and body fat shape the growth-hormone pulse. Nine are infusions in critically ill patients in one Belgian intensive-care unit, in Leuven. Five are diagnostic-test studies, five gave the compound repeatedly for weeks or months, and one measured how much people ate. The compound also had something most in this library never had: a sponsor, a phase I study and a drug approval in Japan in 2004 — as a diagnostic, not a treatment. This file takes the record apart and says what each piece can carry.
264 records in the corpus; 59 typed as clinical trials
38 of the 59 trials share one author, Johannes Veldhuis
1 drug approval, Japan, 22 October 2004 — as a diagnostic, not a treatment
How large this literature is, and when it was written
The 59 trial-typed records, sorted by what was actually given to whom
The development programme: a phase I study, a phase II licence and a Japanese approval
The intensive-care programme: nine studies, five days, no survival endpoint
What has never been measured
5 more sections in the Evidence File for GHRP-2
Unlock the Evidence File, Sourcing File and Benefit & Outcome Review for GHRP-2 for $14 — or every compound in the library, plus the printable reference sheets, for $99.
The sections above this one stay free to read without an account.
Sourcing File
The GHRP-2 Sourcing File: An Unnatural Amino Acid, Four Neighbours a Spectrum Must Rule Out, and a Salt That Is 8% Chloride
GHRP-2 is a defined synthetic hexapeptide, which makes it checkable — but it has features that make a careless certificate easy to write. Its second amino acid, D-2-naphthylalanine, does not occur in nature, and the FDA names it as a reason the peptide is hard to characterise. Three of its six residues are the mirror-image D form, so impurities with one of them flipped weigh exactly the same. Four related molecules sit within 110 daltons of it, including the sequence a widely cited 1997 paper printed with a residue missing. And the approved drug in Japan is the dihydrochloride salt, whose weight is about 8% chloride, not peptide. This file turns all of that into questions to put to a certificate of analysis.
818.0 g/mol — and four neighbours between 712 and 887 a spectrum must rule out
3 of 6 residues in the D form, so a mirror-image impurity has the same mass
1 amino acid found nowhere in nature, named by the FDA as a characterisation problem
91.8% — the peptide share of the dihydrochloride salt's weight
What GHRP-2 is, and the registry records that describe it
The four near neighbours a mass spectrum must rule out
The impurities a mass check cannot see
Salt forms and what the label amount means
What the FDA said, and what to ask a supplier
5 more sections in the Sourcing File for GHRP-2
Unlock the Evidence File, Sourcing File and Benefit & Outcome Review for GHRP-2 for $14 — or every compound in the library, plus the printable reference sheets, for $99.
The sections above this one stay free to read without an account.
Benefit & Outcome Review
The GHRP-2 Benefit & Outcome Review: Growth Hormone and Hunger Are Measured in People; What It Is Bought For Is Not
GHRP-2 is bought for a stronger growth-hormone pulse, for body composition and recovery, and sometimes for sleep. The human research is better than for most compounds in this library, and it answers some of those questions directly. It raises growth hormone reliably — well enough to become an approved diagnostic test in Japan. It makes people eat more: in a double-blind, placebo-controlled study, food intake at a buffet rose by a third. It also raises cortisol, ACTH and prolactin. What it is bought for is another matter: no human study measured muscle, fat or strength, a sleep study found no deeper sleep, and the studies that gave it for months to children found growth-hormone pulses without a rise in IGF-1. This review takes each claim in turn and separates what was measured from what is inferred.
+33.5% food intake against placebo, in 19 people, double-blind
0 human studies of muscle, fat or strength after GHRP-2
2 long-term studies in children: growth-hormone pulses up, IGF-1 not
0 change in deep sleep in the one human sleep study
The growth hormone pulse: measured thoroughly, and now a licensed test
Given for months: growth-hormone pulses, and IGF-1 only sometimes
Appetite: the one market claim measured properly in people
Cortisol, prolactin and sleep: effects buyers rarely hear about
Critical illness: blood markers moved, patients were not followed for outcomes
What no benefit claim here can rest on
6 more sections in the Benefit & Outcome Review for GHRP-2
Unlock the Evidence File, Sourcing File and Benefit & Outcome Review for GHRP-2 for $14 — or every compound in the library, plus the printable reference sheets, for $99.
Quick answers about guide scope, access, and educational use context.
What is GHRP-2?
GHRP-2, or pralmorelin, is a synthetic hexapeptide amide, D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2 (PubChem CID 6918245, C45H55N9O6, 818.0 g/mol, CAS 158861-67-7), that acts as a ghrelin-receptor (GHS-R1a) agonist and stimulates the body's own release of growth hormone. Its established human use is as a diagnostic test for growth hormone deficiency in Japan. It has no US drug label; in the US it is sold for research use only.
How is GHRP-2 different from GHRP-6?
They are different molecules that act on the same receptor. GHRP-2 is D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2, 818.0 g/mol; GHRP-6 is His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, 873.0 g/mol. The documented differences are regulatory and clinical: FDA splits GHRP-2 by route on its 503B list, placing only injectable and nasal forms in its safety-risk category, while GHRP-6 sits there without a route qualifier; and GHRP-2 became a Japanese diagnostic test while GHRP-6 did not. GHRP-2 is commonly described as the stronger GH releaser with less appetite stimulation, but a PubMed search for human studies naming both returns 11 records and none of them gave the two to people and compared them.
What is the half-life of GHRP-2?
The measured human figure is an elimination half-life of 0.55 ± 0.14 hours, about 33 minutes, from the one human pharmacokinetic study (ten children, intravenous, PMID 9543135). The 1-2 hour figure this page previously gave is withdrawn. Growth hormone peaked about 25 minutes after the dose. The study was small, in children and intravenous, so treat it as the best available measurement rather than a settled value for adults.
Is GHRP-2 legal or allowed in sport?
There is no US drug label for it, and it is sold in the US as a research chemical only. It is prohibited at all times by WADA under section S2.2.4 (growth hormone releasing factors), so it is banned in sanctioned sport.
What is the FDA's position on GHRP-2?
It depends on which list and which route. On FDA's 503B list for outsourcing facilities, injectable and nasal GHRP-2 is in Category 2, substances that raise significant safety risks, and all other routes are in Category 1, under evaluation. On the 503A list for pharmacies, GHRP-2 is in Category 3, nominated without adequate support. FDA's stated concerns are immunogenicity from aggregation and peptide-related impurities, the difficulty of characterising a peptide with an unnatural amino acid, and reports of serious adverse events in patients who received it — with causality not established. Always follow the laws and regulations that apply to you.
Has GHRP-2 ever been used in mainstream medicine?
Yes, as a measuring instrument rather than a treatment. The GHRP-2 stimulation test is recommended in Japan as an alternative to the insulin tolerance test for diagnosing adult growth hormone deficiency. In 71 adults with pituitary tumours who took all three tests, it identified severe deficiency with 81.3% sensitivity and 94.5% specificity against the insulin tolerance test (Kinoshita et al., Endocr J 2013, PMID 23079545). Treatment programmes in the US and Japan were planned in the early 2000s but no treatment indication was ever approved.
Are there registered clinical trials of GHRP-2?
None was found, but the flat “no” this page gave before is withdrawn, together with its claim that there was no development programme. ClinicalTrials.gov returns 0 studies with GHRP-2 or pralmorelin as the intervention, while a control search for growth hormone secretagogue returns 257, so the query itself works. GHRP-2 was, however, developed by drug companies: a phase I study in children (PMID 9543135), a Wyeth phase II programme, and approval in Japan on 22 October 2004 as a diagnostic agent (KEGG DRUG D02040). Most of that ran before public trial registration was routine, and Japan's registry could not be checked, so we do not state whether any of those trials was registered.
Does GHRP-2 raise cortisol or prolactin?
In people, yes, modestly. In six healthy young adults, intravenous GHRP-2 raised prolactin, ACTH and cortisol as well as growth hormone; the prolactin rise was smaller than the one TRH produces and the ACTH/cortisol rise was similar to CRH's (Arvat et al., Peptides 1997, PMID 9285939). In rats the developer saw ACTH and corticosterone rise but not prolactin (PMID 15646370), so animal results do not settle the human question.
Compliance and trust notes
Educational content only; no personalized health or outcome claims.
No personalized use recommendation outputs.
Use this material for general learning and research-context literacy.
A certificate of analysis (COA) is a laboratory’s report on one sample of one batch. The single most useful thing to know about it is that purity and identity are two separate results that fail in different ways. A high purity figure says the sample was mostly one substance; it does not say that substance was GHRP-2. Identity — normally a mass-spectrometry result matching the expected molecular weight — is what establishes what the material actually is, and a certificate reporting purity alone has not answered that question.
Two further limits are worth holding onto. Mass per vial is its own test: a vial can be 99% pure and still contain less material than the label claims. And sterility, endotoxin, heavy metals and residual solvent screening are separately commissioned tests, usually priced individually — so a “third-party tested” badge asserts none of them unless the certificate names them. Check that the batch or lot number on the document matches the vial in front of you; an unmatched certificate describes someone else’s material.
Medibact does not test, endorse or resell peptides, and publishes no rating of any laboratory. How to read a peptide certificate of analysis walks through the document section by section, and what each COA field establishes covers the field-by-field detail and the laboratories that publish their methods.
You’ll need bacteriostatic water
The diluent for reconstituting GHRP-2
Reconstitution is volume arithmetic — it assumes a lyophilized vial is dissolved in bacteriostatic water, which is sterile water preserved with 0.9% benzyl alcohol. The preservative is what allows a vial to be entered more than once; plain sterile water carries none and is single-entry by design. Medibact supplies USP-grade Bacteriostatic Water for Injection in a 30 mL multi-dose vial, made in the United States and shipped from the United States, for research use only. One 30 mL vial covers 30 reconstitutions at 1 mL each, 15 at 2 mL, or 10 at 3 mL — division only, not a dosing recommendation.
Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.
